Alzamend Neuro regains compliance with Nasdaq

Alzamend Neuro announced that it has received a notification letter from Nasdaq, informing Alzamend that it has regained compliance with Nasdaq Listing Rule 5550. In order to regain compliance, Alzamend’s common stock was required to maintain a closing bid price of at least $1.00 per share for a minimum of ten consecutive trading days. The minimum bid price requirement was met on July 29. Accordingly, in the compliance notice, Nasdaq stated that the matter is now closed.